Skip to main content Back to Top


Bacitracin Ophthalmic Ointment

Products Affected - Description

    • Bacitracin ophthalmic ointment, Perrigo, 500 unit/gram, 3.5 gram tube, NDC 00574-4022-35

Reason for the Shortage

    • In early-July 2019, Altaire recalled several lots of certain ophthalmic ointments, including bacitracin ophthalmic ointment. The products were recalled due to a potential for nonsterility. Additional information, including the specific lots affected, is available at
    • Altaire manufactures bactracin ophthalmic ointment and Perrigo distributes the product.

Available Products

    • There are no presentations available

Estimated Resupply Dates

    • Perrigo has bacitracin ophthalmic ointment 3.5 gram tubes on back order and the company estimates a release date of late-December 2019 to early-January 2020.


Updated November 6, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created July 26, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins